• Vifor Fresenius snap up rights to Cara’s itch therapy pharmafile
    May 25, 2018
    The joint partnership between Vifor Pharma and Fresenius Medical Care, Vifor Fresenius, has put down $50 in upfront cash and an equity investment of $20 million to gain the Ex-US, Japan and South Korea rights to Cara Therapeutics’ Korsuva.
PharmaSources Customer Service